(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 41.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Tarsus Pharmaceuticals's revenue in 2026 is $366,100,000.On average, 9 Wall Street analysts forecast TARS's revenue for 2026 to be $28,996,559,134, with the lowest TARS revenue forecast at $25,138,784,472, and the highest TARS revenue forecast at $32,501,581,734. On average, 8 Wall Street analysts forecast TARS's revenue for 2027 to be $37,504,208,759, with the lowest TARS revenue forecast at $33,280,098,320, and the highest TARS revenue forecast at $41,261,379,042.
In 2028, TARS is forecast to generate $43,255,637,995 in revenue, with the lowest revenue forecast at $37,440,110,610 and the highest revenue forecast at $51,278,518,840.